A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

Phase 4 Completed 145 enrolled Eisai Inc.

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-center, open-label study of 28 weeks duration in subjects with Mild Cognitive Impairment who have completed the double-blind study (E2020-A001-412).

Timeline

Start: 2006-02
Primary completion: 2007-09
Completion: 2007-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Donepezil	Small molecule	5 mg	Oral
Subject	Donepezil	Small molecule	10 mg	Oral

A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

Summary

Timeline

Drugs

Indications